Your browser doesn't support javascript.
loading
Serum profiling identifies ibrutinib as a treatment option for young adults with B-cell acute lymphoblastic leukaemia.
Jordaens, Stephanie; Cooksey, Leah; Bonney, Stephanie; Orchard, Laurence; Coutinho, Matthew; Van Tendeloo, Viggo; Mills, Ken I; Orchard, Kim; Guinn, Barbara-Ann.
Afiliação
  • Jordaens S; Department of Biomedical Sciences, University of Hull, Hull, UK.
  • Cooksey L; Vaccine & Infectious Disease Institute, Laboratory of Experimental Hematology, University of Antwerp, Antwerpen, Belgium.
  • Bonney S; Department of Biomedical Sciences, University of Hull, Hull, UK.
  • Orchard L; Cancer Sciences Unit, Somers Cancer Sciences Building, University of Southampton, Southampton, UK.
  • Coutinho M; Cancer Sciences Unit, Somers Cancer Sciences Building, University of Southampton, Southampton, UK.
  • Van Tendeloo V; Department of Biomedical Sciences, University of Hull, Hull, UK.
  • Mills KI; Vaccine & Infectious Disease Institute, Laboratory of Experimental Hematology, University of Antwerp, Antwerpen, Belgium.
  • Orchard K; Centre for Cancer Research and Cell Biology, Queens University Belfast, Belfast, UK.
  • Guinn BA; Department of Haematology, University Hospital Southampton NHS Foundation Trust and University of Southampton, Southampton, UK.
Br J Haematol ; 189(3): 500-512, 2020 05.
Article em En | MEDLINE | ID: mdl-32064588
Acute lymphoblastic leukaemia (ALL) is a haematological malignancy that is characterized by the uncontrolled proliferation of immature lymphocytes. 80% of cases occur in children where ALL is well understood and treated. However it has a devastating affects on adults, where multi-agent chemotherapy is the standard of care with allogeneic stem cell transplantation for those who are eligible. New treatments are required to extend remission and prevent relapse to improve patient survival rates. We used serum profiling to compare samples from presentation adult B-ALL patients with age- and sex-matched healthy volunteer (HV) sera and identified 69 differentially recognised antigens (P ≤ 0·02). BMX, DCTPP1 and VGLL4 showed no differences in transcription between patients and healthy donors but were each found to be present at higher levels in B-ALL patient samples than HVs by ICC. BMX plays a crucial role in the Bruton's Tyrosine Kinase (BTK) pathway which is bound by the BTK inhibitor, ibrutinib, suggesting adult B-ALL would also be a worthy target patient group for future clinical trials. We have shown the utility of proto-array analysis of B-ALL patient sera, predominantly from young adults, to help characterise the B-ALL immunome and identified a new target patient population for existing small molecule therapy.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Piperidinas / Adenina / Leucemia-Linfoma Linfoblástico de Células Precursoras B / Linfoma de Células B Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Piperidinas / Adenina / Leucemia-Linfoma Linfoblástico de Células Precursoras B / Linfoma de Células B Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2020 Tipo de documento: Article